Acute Myeloid Leukemia Therapeutics Market to 2020 - Novel Therapies to Offer Clinical Benefit in Small Patient Cohorts

1
Acute Myeloid Leukemia Therapeutics Market to
2020 - Novel Therapies to Offer Clinical Benefit
in Small Patient Cohorts
Single User License - 4995 Site User License
- 9990 Corporate User License -
14985 Publication Date - Sep 2014 Pages -
163 To know more details, email to
debora_at_reportstack.com
2
Summary

• Treatment and prognosis in AML is strongly
  influenced by a patientâs age, and their
  cytogenetic profile. In the majority of cases
  these two prognostic influences are linked, with
  a higher frequency of unfavorable cytogenetic
  abnormalities observed in the elderly. Survival
  in this cohort of elderly patients is very poor,
  with a five year overall survival of 3â8
  (Luger, 2010). Despite a relatively advanced
  understanding of genetic abnormalities associated
  with AML, the introduction of targeted therapies
  is lagging in this indication in comparison to
  other cancers such as breast and lung cancer,
  with no approved targeted therapies. Such slow
  development may be a reflection of AMLs status as
  an orphan indication.

3
Scope

• A brief introduction to AML, including the
  diseaseâs pathogenesis, risk factors and
  diagnosis 
• An in-depth analysis of the drug combinations
  used in the treatment of AML, including analyses
  of their safety, efficacy, and place in the
  disease treatment algorithm. This includes a heat
  map comparing the drug combinations in terms of
  safety and efficacy 
• A comprehensive review of the pipeline for AML
  therapies, including individual analysis of a
  number of late-stage pipeline drugs that have the
  potential to enter the market during the forecast
  period. The pipeline is analyzed on the basis of
  Phase distribution, molecule types and molecular
  targets, as well as administration routes 

4
Key Benefits

• Understand the efficacy and safety of the current
  monotherapies and drug combinations used in the
  treatment of AML, with in-depth analysis of the
  disease treatment algorithm 
• Understand the key signaling pathways and
  molecular targets currently under investigation
  in drug development for AML 
• Understand the vast scope of the pipeline,
  including which molecule types and molecular
  targets are most prominent 
• Observe the trends in clinical trial duration and
  size by clinical phase and molecule type, and use
  the clinical trial failure rate analysis to
  assess the risk profiles of current and/or future
  developmental programs for AML cancer
  therapeutics 
• Assess the potential clinical and commercial
  impact of current late-stage pipeline molecules
  in the AML therapeutics market 

5
If you are interested...
Contact Debora White Email
debora_at_reportstack.com Ph1-888-789-6604 http/
/www.reportstack.com